ArticleHereditas2025
Delving into the pinnacle: an in-depth analysis of the top 100 most cited articles on cardio-oncology.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The intersection of myocardial diseases and cancer therapy-induced cardiovascular toxicity has garnered significant attention in recent years. As the field of cardio-oncology bridges cardiology and oncology, research is expanding rapidly. This study analyzes the top 100 most cited papers (T100) in cardio-oncology, providing valuable insights into current trends and key research areas. Using Microsoft Excel 2009, we conducted a comprehensive temporal analysis of publications and citations. To visualize complex networks involving co-citations, countries, and author keywords, we utilized VOSviewer software. Additionally, Citespace was employed to identify clusters of keywords experiencing notable citation surges. The T100 selection includes 81 clinical research papers and 19 foundational studies. Key journals such as the European Heart Journal and the Journal of the American College of Cardiology stand out, collectively accumulating over 700 citations (9 papers from European Heart Journal and 7 from Journal of the American College of Cardiology). Notably, the United States leads the field with 41 publications and 2,868 citations, excluding self-citations. Prominent keywords emerging in this area include “cardiovascular diseases” (strength 2.48, 2019–2022), “management” (average publication year: September 2019, occurrence: 11 times), and “immune checkpoint inhibitors” (average publication year: 2020, occurrence: 5 times). While the T100 predominantly comprises clinical research, there is a discernible gap in foundational studies exploring the mechanisms of myocardial diseases induced by cancer therapy-related cardiovascular toxicity. The USA continues to dominate this field. Research in cardio-oncology focuses on cardiovascular diseases, especially heart failure and atrial fibrillation, with an emphasis on comprehensive management strategies and the potential of immune checkpoint inhibitors. This study offers valuable insights that could enhance our understanding and management of cardio-oncological complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.